A 75-year-old man with hyperdynamic septic shock and vasodilation was successfully supported hemodynamically for 88.5 hours through the use of a continuous infusion of phenylephrine at dosages up to 360 μg/min. The only other vasoactive compound administered was dopamine at a dosage of 3.4 μg/kg/min. Hemodynamic evaluation indicated improvements in mean arterial pressure, cardiac output, and oxygen transport parameters during the period of hemodynamic support, which did not indicate a detrimental effect on perfusion of vital organs and tissues despite the use of this vasoconstrictor. Phenylephrine's pharmacologic properties may represent an advantage for its use as a vasoconstrictor over catecholamines such as norepinephrine and dopamine, particularly in patients who develop tachyarrhythmias with these agents. The pharmacology, dosage, and appropriate monitoring of therapy with phenylephrine in patients with septic shock are discussed.
Get full access to this article
View all access options for this article.
References
1.
DastaJF. Norepinephrine in septic shock: Renewed interest in an old drug. DICP Ann Pharmacother1990; 24: 153–6.
2.
StarkeKDochertyJR. Alpha-1 and alpha-2-adrenoreceptors: Pharmacology and clinical implications. J Cardiovasc Pharmacol1981; 3 (suppl D): S14–23.
3.
ZaritskyALChernowB. Catecholamines and other inotropes. In: ChernowB, ed. The pharmacologic approach to the critically ill patient. 2nd ed.Baltimore: Williams & Wilkins; 1988: 584–602.
4.
RecordKE. Sepsis and septic shock. In: DiPiroJTTalbertRLHayesPEYeeGCPoseyLM, eds. Pharmacotherapy: A pathophysiologic approach. New York: Elsevier; 1989: 1258–65.
JacobsonLTurnquistKMasleyS. Wolff-Parkinson-White syndrome: Termination of paroxysmal supraventricular tachycardia with phenylephrine. Anaesthesia1985; 40: 657–60.
7.
BrownCGTaylorRBWermanHA, Myocardial oxygen delivery/consumption during cardiopulmonary resuscitation: A comparison of epinephrine and phenylephrine. Ann Emerg Med1988; 17: 302–8.
8.
SiegelJHGreenspanMDel GuercioLR. Abnormal vascular tone, defective oxygen transport, and myocardial failure in human septic shock. Ann Surg1967; 165: 504–16.
9.
EdwardsJDBrownCSNightengaleP, Use of survivors' cardiorespiratory values as therapeutic goals in septic shock. Crit Care Med1989; 17: 1098–103.
10.
RuffoloRR. Cardiovascular adrenoreceptors: Physiology and critical care implications. In: ChernowB, ed. The pharmacologic approach to the critically ill patient. 2nd ed.Baltimore: Williams & Wilkins; 1988: 166–83.
11.
ShoemakerWCKramHBAppelPL. Therapy of shock based on pathophysiology, monitoring, and outcome prediction. Crit Care Med1990; 18 (suppl): S19–25.
12.
ParkerMMParrilloJE. Septic shock and other forms of distributive shock. In: ParrilloJE, ed. Current therapy in critical care medicine. Philadelphia: BC Decker; 1987: 44–55.
13.
ShoemakerWCAppelPLKramHB, Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest1988; 94: 1176–86.
14.
YamazakiTShimidaYTaenakaN, Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. Crit Care Med1982; 10: 432–5.
15.
ChernowBRothBL. Pharmacologic manipulation of the peripheral vasculature in septic shock: Clinical and experimental approaches. Circ Shock1986; 18: 141–55.
16.
MosherPRossJMcFateP, Control of coronary blood flow by an autoregulatory mechanism. Circ Res1964; 14: 250–9.
17.
ShavitGSagyMNadlerE, Myocardial response to alpha-agonist (phenylephrine) in relation to age. Crit Care Med1989; 17: 1324–7.
18.
HengstmannJHGoronzyJ. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol1982; 21: 335–41.
19.
SchwinnDARevesJG. Time course and hemodynamic effects of alpha-1 adrenergic bolus administration in anesthetized patients with myocardial disease. Anesth Analg1989; 68: 571–8.
20.
GasicSEichlerHGKornA. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects. J Cardiovasc Pharmacol1985; 7: 219–23.
21.
MartinssonABevegardSHjemdahlP. Analysis of phenylephrine in plasma: Initial data about the concentration-effect relationship. Eur J Clin Pharmacol1986; 30: 427–31.
22.
McNayJLGoldbergLI. Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow. J Pharmacol Exp Ther1966; 151: 23–31.
23.
McDonaldRHGoldbergLIMcNayJL, Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest1964; 43: 1116–24.
24.
SchaerGLFinkMPParrilloJE. Norepinephrine alone versus norepinephrine plus low-dose dopamine: Enhanced renal blood flow with combination pressor therapy. Crit Care Med1985; 13: 492–6.
25.
De La CalMAMiravallesEPascualT, Dose-related hemodynamic and renal effects of dopamine in septic shock. Crit Care Med1984; 12: 22–5.
